Author

Michael P. Sterba

Observed name: Michael Sterba

Institution: Orbus Therapeutics (United States)

Observed institutions: Orbus Therapeutics (United States), Rigel (United States), Plexxikon (United States)

OpenAlex ID: A5049196541

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 · Jonathan W. Friedberg, Jeff Sharman, et al. · Blood · 747

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

2024 · Joe S Mendez, Adam L Cohen, et al. · Neuro-Oncology Advances · 11

Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.

2021 · Michael S. Gordon, Richard D. Carvajal, et al. · Journal of Clinical Oncology · 7

Works count: 4

Citation count: 765

H-index: 3

I10-index: 2